Presented by expert speakers, our webinars will give you advance insight into topics that will be covered at the event.
Can’t make the date? Still register to receive the webinar recording afterwards.
The Dynamics of Sars-CoV-2-Specific Antibody Responses in COVID-19 Patients
Tuesday 8th December 2020 | 14:30 GMT
Presented by Christine S. Falk, PhD., Full Professor for Transplant Immunology; Director, Institute of Transplant Immunology at Hannover Medical School
- Immunological background of Sars-CoV-2-specific antibody responses and antibody class switching
- Key features of the multiplex technology for antibody responses
- Kinetics of SARS-CoV-2 specific antibodies in severe COVID-19 patients
- What do we need to know about antibody responses for vaccination against SARS-CoV-2?
Since the beginning of this pandemic, an extremely large body of information on immune responses on COVID-19 patients has been published demonstrating the massive deterioration of the systemic immune network by this respiratory virus. The worldwide effort to understand humoral and cellular immune responses specific for this zoonotic virus resulted in the most detailed knowledge ever of the interaction between SARS-CoV-2 and the different patients’ groups, ranging from mild to intermediate to severe COVID-19 diseases. Antibody responses specific for several SARS-CoV-2 proteins have also been studied extensively with different assays and especially Spike- and receptor-binding-protein domain-specific IgG and IgA antibodies have been shown to be clinically relevant.
In this seminar, we would like to discuss the immunological background for the impact of the isotypes IgM, IgG and IgA during SARS-CoV-2-specific antibody responses in severe COVID-19 patients and during the convalescent phase. In addition, we would like to comment on assay specificity versus “pre-existing” cross-reactive antibodies. All of these aspects are of great importance with respect to all current vaccination strategies because the success depends on the immunological “correlates of protection” that are still incompletely understood.
The MILLIPLEX® SARS-CoV-2 IgG, IgM, IgA assays used here are for Research Use Only. Not For Use In Diagnostic Procedures.
Christine S. Falk, PhD., is full professor for Transplant Immunology and director of the Institute of Transplant Immunology at Hannover Medical School (MHH). She focusses on mechanisms of ischemia/reperfusion injury and consequences for innate and adaptive immunity, especially tissue-resident T and NK cells in the context of lung, heart and kidney transplantation. She graduated as PhD at the Institute of Immunology at Ludwig-Maximilians University in Munich, Germany, in the field of tumor immunology and continued to work on T and NK cell recognition of solid tumors as postdoc fellow at the Institute of Molecular Immunology, Helmholtz Centre Munich. In 2004, she received her Venia Legendi at LMU for Human Immunology. 2006-2010, she worked at the German Cancer Research Centre (DKFZ) in Heidelberg, Germany, as group leader of the Research Group “Immune Monitoring” with a strong interest in the improvement of cancer immunotherapy by understanding the mechanisms involved in treatment resistance.
Christine Falk has a long-term research interest in transplant and tumor immunology and the interface to infectious diseases in solid organ transplantation. Major aspects of her research are tissue-resident lymphocytes and the identification of “common denominators” of tumor vs. organ rejection and protection from infection. She published more than 150 peer articles in international peer-reviewed journals and received the Walter Schulz award for Tumor Immunology. At MHH, she is trust lecturer of the DFG, member of dissertation and research committees and vice president of the German Society of Immunology (DGfI). Since 2014, she serves as board member of the German Cancer Aid Foundation and editorial board member of several scientific journals.
Introduction: Multiplex Kits for Detection of IgG, IgM and IgA Antibodies which Recognize SARS CoV-2 Antigens in Human Serum/Plasma Samples
Presented by Christine Kornmeier, Product Manager, MILLIPLEX® and Custom Assays,
Immunoassay Platform Solutions, Life Science Research, MilliporeSigma
- Each MILLIPLEX® SARS-CoV-2 kit detects one immunoglobulin type: IgG, IgM, IgA
- Each MILLIPLEX® SARS-CoV-2 kit is selectable for the antigen(s) you wish to detect: S1, S2, RBD, N
- MILLIPLEX® SARS-CoV-2 assay key points: 96-well assay format; 2 hour primary incubation; 25 µL per well of 1:100 – 1:200 diluted sample; qualitative assay; kits contain positive and negative assay performance verification beads; all readouts are in mean fluorescence intensity (MFI); customers should include COVID negative samples to determine experiment MFI cutoff
In response to the high demands of the research community our R&D Scientists have developed three new MILLIPLEX® multiplex kits, each for the qualitative detection of IgG, IgM or IgA antibodies which recognize the SARS CoV-2 antigens, S1, S2, RBD and N, in human serum/plasma samples. These assays are for research use only (RUO) and not intended for use in clinical or for diagnostic purposes.
I will be welcoming our guest speaker, Christine S. Falk, PhD., Professor for Transplant Immunology and Director of the Institute of Transplant Immunology at Hannover Medical School (MHH), Germany. Dr. Falk will be presenting results from using these new kits to analyze samples from patients determined positive or negative by PCR for COVID-19 disease.
|MILLIPLEX® Assay Kits
96-well Plate Format
|SARS-CoV-2 Antigen Panel 1 IgM
SARS-CoV-2 Antigen Panel 1 IgG
SARS-CoV-2 Antigen Panel 1 IgA
|Available Analytes for Each Panel|
|SARS-CoV-2 Spike Subunit 1 (S1)
SARS-CoV-2 Spike Subunit 2 (S2)
SARS-CoV-2 Receptor Binging Domain (RBD)
SARS-CoV-2 Nucleocapsid Protein (N)
After a career in discovery research biology focusing on Inflammatory Mediators at Pfizer and legacy Pharmacia and G.D. Searle/Monsanto, and then moving to Sigma-Aldrich, Christine Kornmeier joined the MILLIPLEX® Product Management team in 2016. She is currently the Product Manager for the MILLIPLEX® Custom Assays and catalog portfolios for Cancer, Virology, Metabolic and Agricultural Animal Health